This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Corn, B. W. Articles by Curran, W. J. Search for Related Content PubMed PubMed Citation Articles by Corn, B. W. Articles by Curran, W. J., Jr Social Bookmarking                            What's this?

Globalization of the Radiation Therapy Oncology Group: Implementation of a Model for Service Expansion and Public Health Improvement

Benjamin W. Corn, Isaiah D. Wexler, Mohan Suntharalingam, Moshe Inbar, Walter J. Curran, Jr

From the Department of Radiation Oncology; Department of Oncology, Tel Aviv Medical Center, Tel Aviv; Department of Pediatrics, Mount Scopus Campus, Hadassah University Hospital, Jerusalem, Israel; Department of Radiation Oncology, University of Maryland Greenebaum Cancer Center, Baltimore, MD; and the Radiation Oncology Department, Thomas Jefferson University Hospital of the Jefferson Medical College, Philadelphia, PA

Corresponding author: Benjamin W. Corn, MD, Institute of Radiotherapy, Aviv Medical Center, 6 Weizmann St, Aviv, Israel 64239; e-mail: bencorn{at}tasmc.health.gov.il

The Radiation Therapy Oncology Group (RTOG) is part of the cooperative group network that is overseen by the National Cancer Institute (NCI). Although the NCI is a US-based group, it has empowered the cooperative groups to recruit foreign institutions to participate in collaborative clinical trials. The RTOG undertook the challenge of globalizing its efforts in 2004. This article describes the rationale for this decision and the tactics adopted by the first hospital outside of North America to enroll patients onto RTOG trials. The challenges confronted by foreign institutions seeking admission to the RTOG and the mechanism by which Tel Aviv Medical Center (TAMC) met these challenges are described. Shortly after its acceptance, TAMC emerged as one of the leading accruers of patients to RTOG studies. The public health implications of this accomplishment are discussed.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?